MaxCyte (MXCT) Competitors $1.54 -0.08 (-4.94%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.54 0.00 (-0.26%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MXCT vs. BWMN, UXIN, PHLT, NUTX, PRTH, LTBR, NEXN, THRY, ABSI, and IBEXShould you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include Bowman Consulting Group (BWMN), Uxin (UXIN), Performant Healthcare (PHLT), Nutex Health (NUTX), Priority Technology (PRTH), Lightbridge (LTBR), Nexxen International (NEXN), Thryv (THRY), Absci (ABSI), and IBEX (IBEX). These companies are all part of the "business services" industry. MaxCyte vs. Its Competitors Bowman Consulting Group Uxin Performant Healthcare Nutex Health Priority Technology Lightbridge Nexxen International Thryv Absci IBEX Bowman Consulting Group (NASDAQ:BWMN) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Is BWMN or MXCT more profitable? Bowman Consulting Group has a net margin of 2.20% compared to MaxCyte's net margin of -125.22%. Bowman Consulting Group's return on equity of 5.62% beat MaxCyte's return on equity.Company Net Margins Return on Equity Return on Assets Bowman Consulting Group2.20% 5.62% 2.67% MaxCyte -125.22%-22.12%-19.10% Do analysts prefer BWMN or MXCT? Bowman Consulting Group currently has a consensus price target of $38.17, indicating a potential downside of 8.89%. MaxCyte has a consensus price target of $7.00, indicating a potential upside of 354.55%. Given MaxCyte's higher probable upside, analysts clearly believe MaxCyte is more favorable than Bowman Consulting Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bowman Consulting Group 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60MaxCyte 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media refer more to BWMN or MXCT? In the previous week, Bowman Consulting Group had 7 more articles in the media than MaxCyte. MarketBeat recorded 11 mentions for Bowman Consulting Group and 4 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.88 beat Bowman Consulting Group's score of 0.55 indicating that MaxCyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bowman Consulting Group 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, BWMN or MXCT? Bowman Consulting Group has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Bowman Consulting Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBowman Consulting Group$426.56M1.69$3.03M$0.6069.82MaxCyte$38.63M4.25-$41.06M-$0.43-3.58 Do insiders & institutionals hold more shares of BWMN or MXCT? 63.2% of Bowman Consulting Group shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 17.4% of Bowman Consulting Group shares are owned by insiders. Comparatively, 3.3% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, BWMN or MXCT? Bowman Consulting Group has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. SummaryBowman Consulting Group beats MaxCyte on 12 of the 16 factors compared between the two stocks. Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MXCT vs. The Competition Export to ExcelMetricMaxCyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.70M$3.38B$6.11B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E Ratio-3.5822.1185.5826.57Price / Sales4.25461.00613.00132.62Price / CashN/A47.2238.5062.09Price / Book0.7910.2112.756.53Net Income-$41.06M-$52.40M$3.31B$276.43M7 Day Performance-9.94%0.86%0.81%-0.86%1 Month Performance4.05%10.39%6.22%3.58%1 Year Performance-60.31%27.24%80.35%37.94% MaxCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MXCTMaxCyte3.3118 of 5 stars$1.54-4.9%$7.00+354.5%-58.4%$172.70M$38.63M-3.5880BWMNBowman Consulting Group1.9674 of 5 stars$42.10+1.5%$38.17-9.3%+95.4%$715.22M$426.56M70.172,200Analyst DowngradeUXINUxin0.5542 of 5 stars$3.45-1.1%N/A-43.4%$648.55M$1.63B-16.43810PHLTPerformant Healthcare1.1371 of 5 stars$7.71-0.1%$7.88+2.1%N/A$621M$122.98M-771.00930News CoverageAnalyst ForecastNUTXNutex Health2.9385 of 5 stars$108.62+0.7%$252.50+132.5%+401.2%$599.29M$479.95M9.141,150Trending NewsAnalyst ForecastPRTHPriority Technology4.2778 of 5 stars$7.03+0.7%$13.00+84.9%+15.0%$557.83M$879.70M27.041,019Trending NewsAnalyst ForecastAnalyst RevisionLTBRLightbridge0.721 of 5 stars$22.68+6.9%N/A+605.4%$549.66MN/A-27.336News CoverageAnalyst ForecastInsider TradeNEXNNexxen International4.3603 of 5 stars$8.36-2.7%$15.00+79.4%+6.0%$544.75M$365.48M13.27895News CoverageAnalyst ForecastTHRYThryv1.992 of 5 stars$11.83-0.9%$20.50+73.3%-36.8%$524.60M$824.16M-4.993,016Analyst ForecastABSIAbsci3.0418 of 5 stars$3.76+11.2%$7.98+112.2%-2.9%$505.39M$4.53M-4.00210Analyst ForecastIBEXIBEX1.248 of 5 stars$37.61-0.8%$34.50-8.3%+86.8%$504.91M$558.27M15.7433,000Analyst Forecast Related Companies and Tools Related Companies Bowman Consulting Group Alternatives Uxin Alternatives Performant Healthcare Alternatives Nutex Health Alternatives Priority Technology Alternatives Lightbridge Alternatives Nexxen International Alternatives Thryv Alternatives Absci Alternatives IBEX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MXCT) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
